Company intelligence / Profile preview
Ribomic Inc.
Tokyo, Japanribomic.com ↗
- Ownership
- Public · 4591
- Employees
- ~24
- Development stage
- Other
01
Overview
Ribomic has developed a pipeline of RNA aptamer-based therapeutics targeting a range of diseases including osteoarthritis (RBM-010), with ongoing research in several other indications. The company’s lead candidate RBM‑010 targets ADAMTS5 for the treatment of osteoarthritis and has shown promise in preclinical studies[3]. Other programs are at various early development stages.
- Therapeutic areas
- PulmonologyCardiovascularRheumatologyOphthalmologyRare Diseases
- Modalities
- RNA aptamers
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Financials
- Market cap
- $20M
- Total revenue
- $19K
- Enterprise value
- $2.4M
Beyond the preview
Go deeper on Ribomic Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribomic Inc..